{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:17:27Z","timestamp":1761175047299,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ijid.2021.06.035","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T06:41:28Z","timestamp":1624430488000},"page":"108-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Cefiderocol treatment of Pseudomonas aeruginosa and extensively drug-resistant Acinetobacter baumannii retained spinal hardware infection causing reversible acute interstitial nephritis"],"prefix":"10.1016","volume":"109","author":[{"given":"Kimberly","family":"Cipko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Kizny Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Konecny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ijid.2021.06.035_bib0001","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01872-19","article-title":"Long-term compassionate use of cefiderocol to treat chronic osteomyelitis caused by extensively drug-resistant Pseudomonas aeruginosa and extended-spectrum-\u03b2-lactamase-producing Klebsiella pneumoniae in a pediatric patient","volume":"64","author":"Alamarat","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.06.035_bib0002","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","author":"Bassetti","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2021.06.035_bib0003","unstructured":"Bell SM, Pham JN, Rafferty DL, Allerton JK, James PM. Antibiotic susceptibility testing by the CDS method. A manual for medical and veterinary laboratories, 9th Ed. Kogarah (Australia): The CDS Reference Laboratory; 2018. http:\/\/cdstest.net\/manual. [accessed 20 May 2021]"},{"key":"10.1016\/j.ijid.2021.06.035_bib0004","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00948-19","article-title":"Coinfections of two strains of NDM-1- and OXA-232-coproducing Klebsiella pneumoniae in a kidney transplant patient","volume":"64","author":"Contreras","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.ijid.2021.06.035_bib0005","doi-asserted-by":"crossref","first-page":"ofaa150","DOI":"10.1093\/ofid\/ofaa150","article-title":"Case report: Successful rescue therapy of extensively drug-resistant Acinetobacter baumannii osteomyelitis with cefiderocol","volume":"7","author":"Dagher","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"10.1016\/j.ijid.2021.06.035_bib0006","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/cid\/ciy963","article-title":"Compassionate use of cefiderocol as adjunctive treatment of native aortic valve endocarditis due to extremely drug-resistant Pseudomonas aeruginosa","volume":"68","author":"Edgeworth","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.ijid.2021.06.035_bib0007","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/ppul.24945","article-title":"Combining bacteriophages with cefiderocol and meropenem\/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient","volume":"55","author":"Gainey","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ijid.2021.06.035_bib0008","doi-asserted-by":"crossref","first-page":"e00863","DOI":"10.1016\/j.idcr.2020.e00863","article-title":"Cefiderocol for treatment of an empyema due to extensively drug-resistant Pseudomonas aeruginosa: Clinical observations and susceptibility testing considerations","volume":"21","author":"Kufel","year":"2020","journal-title":"IDCases"},{"key":"10.1016\/j.ijid.2021.06.035_bib0009","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharacol Ther"},{"key":"10.1016\/j.ijid.2021.06.035_bib0010","article-title":"Cefiderocol retains anti-biofilm activity in multi-drug resistant Gram-negative pathogens","author":"Pybus","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.ijid.2021.06.035_bib0011","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3390\/microorganisms8081236","article-title":"Compassionate use of cefiderocol to treat a case of prosthetic joint infection due to extensively drug-resistant Enterobacter hormaechei","volume":"8","author":"Sim\u00e9on","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.ijid.2021.06.035_bib0012","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41579-020-0340-0","article-title":"Critical analysis of antibacterial agents in clinical development","volume":"18","author":"Theuretzbacher","year":"2020","journal-title":"Nat Rev Microbiol"},{"issue":"11","key":"10.1016\/j.ijid.2021.06.035_bib0013","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1093\/jac\/dkz318","article-title":"IMAGES Group. Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report","volume":"74","author":"Trecarichi","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.ijid.2021.06.035_bib0014","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40121-020-00286-6","article-title":"Cefiderocol: a novel agent for the management of multidrug-resistant Gram-negative organisms","volume":"9","author":"Wu","year":"2020","journal-title":"Infect Dis Ther"},{"issue":"6","key":"10.1016\/j.ijid.2021.06.035_bib0015","doi-asserted-by":"crossref","first-page":"ofaa185","DOI":"10.1093\/ofid\/ofaa185","article-title":"Cefiderocol for extensively drug-resistant Gram-negative bacterial Infections: real-world experience from a case series and review of the literature","volume":"7","author":"Zingg","year":"2020","journal-title":"Open Forum Infect Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221005245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221005245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:57:43Z","timestamp":1761119863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971221005245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":15,"alternative-id":["S1201971221005245"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2021.06.035","relation":{},"ISSN":["1201-9712"],"issn-type":[{"type":"print","value":"1201-9712"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cefiderocol treatment of Pseudomonas aeruginosa and extensively drug-resistant Acinetobacter baumannii retained spinal hardware infection causing reversible acute interstitial nephritis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2021.06.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}